{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:43Z","timestamp":1791924763301,"version":"4.3.4"},"reference-count":110,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000545","name":"British Association of Dermatologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000545","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Royal College of Ophthalmologists"},{"name":"National Health Service"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Atopic dermatitis (AD) is the most common inflammatory skin condition and affects people of all ages. New therapies, including the monoclonal antibody therapy dupilumab, offer excellent efficacy. However, in clinical trials, and emphasized in real-world observations, an unexpected increased frequency of ocular adverse effects has become apparent. The effectiveness of dupilumab and the unpredictability of ocular adverse effects mean that clinicians need guidance on counselling patients prior to treatment and on managing them if adverse effects arise. The British Association of Dermatologists (BAD) and Royal College of Ophthalmologists collaborated on this consensus guidance on managing dupilumab-related ocular surface disorders (DROSD). A multidisciplinary group was formed of adult and paediatric dermatologists and ophthalmologists with expertise in DROSD, patient representatives and the BAD Clinical Standards Unit. A literature search was conducted and the results reviewed. All recommendations were reviewed, discussed and voted on. The recommendations pertain to dermatology and ophthalmology management, and apply to people of all ages, unless otherwise stated. Importantly, initiation of dupilumab for AD should not be delayed for most eye disorders except acute new problems (e.g. infections) or potentially severe conditions (e.g. a history of corneal transplant; ophthalmology advice should be sought first). There is insufficient evidence to recommend lubricant drops prophylactically. Dermatologists should assess eye complaints to diagnose DROSD; a severity grading system is provided. DROSD management differs slightly in those aged &amp;lt; 7\u2005years, as ocular complications may affect neuro-ocular development. Therefore, irrespectively of DROSD severity, this population should be referred for ophthalmology advice. In those aged \u2265 7\u2005years, dermatologists should feel confident to trial treatment and reserve ophthalmology advice for severe or nonresponding cases. Discussion about dupilumab withdrawal should be prompted by a significant impact on quality of life, threat to sight, or other complications. Although dupilumab is a highly effective agent for treating AD, the risk of ocular adverse effects should not inhibit clinicians or patients from using it, but clinicians should be aware of them. If a patient develops DROSD, there are clear pathways to assess severity and offer initial management. Where this is ineffective, dermatologists should assess the urgency and seek advice from or initiate referral to ophthalmology. While the evidence reviewed for these guidelines reflects the extensive literature on dupilumab, we believe our advice has relevance for ocular surface disorders in patients with AD treated with tralokinumab and lebrikizumab.<\/jats:p>","DOI":"10.1093\/bjd\/ljae344","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T19:47:55Z","timestamp":1725565675000},"page":"865-885","source":"Crossref","is-referenced-by-count":36,"title":["An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024"],"prefix":"10.1093","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1466-2016","authenticated-orcid":false,"given":"Michael R","family":"Ardern-Jones","sequence":"first","affiliation":[{"name":"Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital , Southampton SO16 6YD ,","place":["UK"]},{"name":"Department of Dermatology, University Hospital Southampton NHS Foundation Trust , Southampton SO16 6YD ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3232-5251","authenticated-orcid":false,"given":"Sara J","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal Infirmary of Edinburgh , Lauriston Place, Edinburgh EH3 9EN ,","place":["UK"]},{"name":"Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh , Crewe Road, Edinburgh EH4 2XU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4884-6286","authenticated-orcid":false,"given":"Carsten","family":"Flohr","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London SE1 9RT ,","place":["UK"]},{"name":"King\u2019s College London , London WC2R 2LS ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-2395","authenticated-orcid":false,"given":"Parwez","family":"Hossain","sequence":"additional","affiliation":[{"name":"Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital , Southampton SO16 6YD ,","place":["UK"]},{"name":"Eye Unit, University Hospital Southampton NHS Foundation Trust, Southampton General Hospital , Southampton SO16 6YD ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9048-2044","authenticated-orcid":false,"given":"Alan\u00a0D","family":"Irvine","sequence":"additional","affiliation":[{"name":"Clinical Medicine, Trinity College Dublin , Dublin D02 PN40 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7494-0765","authenticated-orcid":false,"given":"Graham A","family":"Johnston","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospitals of Leicester NHS Trust , Leicester LE2 0TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lane","sequence":"additional","affiliation":[{"name":"Ophthalmology, Institute of Inflammation and Ageing, University of Birmingham , Birmingham B15 2TT ,","place":["UK"]},{"name":"Birmingham and Midland Eye Centre, Sandwell and West Birmingham NHS Trust , Birmingham B18 7QH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7022-7441","authenticated-orcid":false,"given":"Sin\u00e9ad M","family":"Langan","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London SE1 9RT ,","place":["UK"]},{"name":"Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine , London WC1E 7HT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4628-0699","authenticated-orcid":false,"given":"Philip","family":"Laws","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leeds Teaching Hospitals NHS Trust , Leeds LS7 4SA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0981-5228","authenticated-orcid":false,"given":"Daniel","family":"O\u2019Driscoll","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Southampton NHS Foundation Trust , Southampton SO16 6YD ,","place":["UK"]},{"name":"Department of Dermatology, Imperial College Healthcare NHS Trust , London W12 0HS ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-6114","authenticated-orcid":false,"given":"Donal","family":"O\u2019Kane","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Belfast Health and Social Care Trust , Belfast BT9 7AB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Payne","sequence":"additional","affiliation":[{"name":"Patient representative"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8113-0373","authenticated-orcid":false,"given":"Gabriela","family":"Petrof","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Great Ormond Street Hospital for Children , London WC1N 3JH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-5539","authenticated-orcid":false,"given":"Andrew\u00a0E","family":"Pink","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London SE1 9RT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4627-3496","authenticated-orcid":false,"given":"Saaeha","family":"Rauz","sequence":"additional","affiliation":[{"name":"Ophthalmology, Institute of Inflammation and Ageing, University of Birmingham , Birmingham B15 2TT ,","place":["UK"]},{"name":"Birmingham and Midland Eye Centre, Sandwell and West Birmingham NHS Trust , Birmingham B18 7QH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8153-5677","authenticated-orcid":false,"given":"Scott","family":"Robbie","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London SE1 7EH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1645-4993","authenticated-orcid":false,"given":"Sri K","family":"Gore","sequence":"additional","affiliation":[{"name":"Clinical and Academic Department of Ophthalmology, Great Ormond Street Hospital for Children , London WC1N 3JH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mili","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Liverpool University Hospitals NHS Trust , Liverpool L13 4LB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3200-0075","authenticated-orcid":false,"given":"Richard T","family":"Woolf","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London SE1 9RT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Standards Unit, British Association of Dermatologists , Willan House, London W1T 5HQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stoyana","family":"Tumbeva","sequence":"additional","affiliation":[{"name":"Clinical Standards Unit, British Association of Dermatologists , Willan House, London W1T 5HQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4070-0696","authenticated-orcid":false,"given":"M Firouz","family":"Mohd Mustapa","sequence":"additional","affiliation":[{"name":"Clinical Standards Unit, British Association of Dermatologists , Willan House, London W1T 5HQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"2024111803541367800_ljae344-B1","author":"National Institute for Health and Care Excellence"},{"key":"2024111803541367800_ljae344-B2","author":"National Institute for Health and Care Excellence"},{"key":"2024111803541367800_ljae344-B3","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","article-title":"Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study","volume":"132","author":"Silverberg","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2024111803541367800_ljae344-B4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2500\/aap.2012.33.3569","article-title":"Epidemiology of atopic dermatitis: a review","volume":"33","author":"DaVeiga","year":"2012","journal-title":"Allergy Asthma Proc"},{"key":"2024111803541367800_ljae344-B5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"2024111803541367800_ljae344-B6","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis","volume":"384","author":"St\u00e4nder","year":"2021","journal-title":"N Engl J Med"},{"key":"2024111803541367800_ljae344-B7","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1172\/JCI115166","article-title":"Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma","volume":"87","author":"Hamid","year":"1991","journal-title":"J Clin Invest"},{"key":"2024111803541367800_ljae344-B8","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI117408","article-title":"Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis","volume":"94","author":"Hamid","year":"1994","journal-title":"J Clin Invest"},{"key":"2024111803541367800_ljae344-B9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jaci.2007.04.031","article-title":"Cytokine modulation of atopic dermatitis filaggrin skin expression","volume":"120","author":"Howell","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"2024111803541367800_ljae344-B10","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.4049\/jimmunol.171.6.3262","article-title":"Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes","volume":"171","author":"Nomura","year":"2003","journal-title":"J Immunol"},{"key":"2024111803541367800_ljae344-B11","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1046\/j.0022-202x.2001.01331.x","article-title":"Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model","volume":"116","author":"Cho","year":"2001","journal-title":"J Invest Dermatol"},{"key":"2024111803541367800_ljae344-B12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1067\/mai.2001.117455","article-title":"Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin","volume":"108","author":"Cho","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"2024111803541367800_ljae344-B13","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"2024111803541367800_ljae344-B14","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"2024111803541367800_ljae344-B15","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9)","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024111803541367800_ljae344-B16","first-page":"100042","article-title":"A literature review of real-world effectiveness and safety of dupilumab for atopic dermatitis","volume-title":"JID Innov","author":"Kamata","year":"2021"},{"key":"2024111803541367800_ljae344-B17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2024111803541367800_ljae344-B18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"2024111803541367800_ljae344-B19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","article-title":"Dupilumab provides acceptable safety and sustained efficacy for up to 4\u2005years in an open-label study of adults with moderate-to-severe atopic dermatitis","volume":"23","author":"Beck","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2024111803541367800_ljae344-B20","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","article-title":"Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab \u2013 clinical characteristics and treatment","volume":"6","author":"Wollenberg","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024111803541367800_ljae344-B21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2021.09.029","article-title":"Dupilumab-induced ocular surface disease: a systematic review","volume":"86","author":"Fachler","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2024111803541367800_ljae344-B22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13555-020-00469-6","article-title":"Real-world experience and laboratory monitoring of dupilumab in patients with moderate to severe atopic dermatitis in a tertiary centre","volume":"11","author":"Kreeshan","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024111803541367800_ljae344-B23","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjd.19631","article-title":"Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single-centre, prospective 1-year observational cohort study of the first 100 patients treated","volume":"184","author":"Sears","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024111803541367800_ljae344-B24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort","volume":"81","author":"Faiz","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2024111803541367800_ljae344-B25","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/ijd.15584","article-title":"Prevalence of ocular disease during dupilumab treatment for atopic dermatitis: a bicentric retrospective comparative cohort study","volume":"60","author":"Barb\u00e9","year":"2021","journal-title":"Int J Dermatol"},{"key":"2024111803541367800_ljae344-B26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/09546634.2019.1682503","article-title":"Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis","volume":"32","author":"Fargnoli","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2024111803541367800_ljae344-B27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.18176\/jiaci.0641","article-title":"Use of dupilumab in 543 adult patients with moderate-to-severe atopic dermatitis: a multicenter, retrospective study","volume":"32","author":"Nettis","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2024111803541367800_ljae344-B28","doi-asserted-by":"crossref","first-page":"e380-3","DOI":"10.1111\/jdv.16219","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real-life Italian tertiary centre experience","volume":"34","author":"Ribero","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024111803541367800_ljae344-B29","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/bjd.21794","article-title":"Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry","volume":"187","author":"St\u00f6lzl","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024111803541367800_ljae344-B30","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jaip.2020.09.042","article-title":"Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis","volume":"9","author":"Achten","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024111803541367800_ljae344-B31","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaad.2020.05.128","article-title":"Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry","volume":"83","author":"Bosma","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024111803541367800_ljae344-B32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2019.10.010","article-title":"Off-label use of dupilumab for pediatric patients with atopic dermatitis: a multicenter retrospective review","volume":"82","author":"Igelman","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024111803541367800_ljae344-B33","article-title":"Retrospective study of dupilumab treatment for moderate to severe atopic dermatitis in Korea: efficacy and safety of dupilumab in real-world practice","volume":"9","author":"Jang","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"2024111803541367800_ljae344-B34","doi-asserted-by":"crossref","first-page":"838030","DOI":"10.3389\/fmed.2022.838030","article-title":"Efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a real-world study","volume":"9","author":"Zhou","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2024111803541367800_ljae344-B35","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjd.20690","article-title":"The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study","volume":"186","author":"Zhao","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024111803541367800_ljae344-B36","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/jdv.18109","article-title":"Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study","volume":"36","author":"Gu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024111803541367800_ljae344-B37","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041031","article-title":"Association between dupilumab and conjunctivitis: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Lin","year":"2023","journal-title":"Pharmaceutics"},{"key":"2024111803541367800_ljae344-B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdin.2021.03.009","article-title":"Encounters and medication use for ocular surface disorders among patients treated with dupilumab: a cohort study","volume":"4","author":"Barbieri","year":"2021","journal-title":"JAAD Int"},{"key":"2024111803541367800_ljae344-B39","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.1128","article-title":"Identification of risk factors for dupilumab-associated ocular surface disease in patients with atopic dermatitis","volume":"102","author":"Achten","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"2024111803541367800_ljae344-B40","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/jdv.17981","article-title":"Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review","volume":"36","author":"Neagu","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"2024111803541367800_ljae344-B41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jdv.16724","article-title":"Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study","volume":"35","author":"Touhouche","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024111803541367800_ljae344-B42","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/jdv.18932","article-title":"Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients","volume":"37","author":"Costedoat","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024111803541367800_ljae344-B43","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/ceo.14142","article-title":"Successful treatment and prevention of the recurrence of refractory vernal keratoconjunctivitis with dupilumab","volume":"50","author":"Tsui","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"key":"2024111803541367800_ljae344-B44","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11\u2005years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024111803541367800_ljae344-B45","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6\u2005months to younger than 6\u2005years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"2024111803541367800_ljae344-B46","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2024111803541367800_ljae344-B47","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.jaip.2022.06.014","article-title":"Dupilumab improves clinical scores in children and adolescents with moderate to severe atopic dermatitis: a real-world, single-center study","volume":"10","author":"Pagan","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024111803541367800_ljae344-B48","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40257-021-00597-5","article-title":"Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study","volume":"22","author":"Patruno","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2024111803541367800_ljae344-B49","doi-asserted-by":"crossref","first-page":"201","DOI":"10.18176\/jiaci.0481","article-title":"Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience","volume":"30","author":"Nettis","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2024111803541367800_ljae344-B50","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jaad.2019.12.039","article-title":"Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting","volume":"82","author":"Uchida","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024111803541367800_ljae344-B51","doi-asserted-by":"crossref","first-page":"e255-6","DOI":"10.1111\/jdv.16234","article-title":"Ocular surface disease during dupilumab treatment in patients with atopic dermatitis, is it possible to prevent it?","volume":"34","author":"Pistone","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024111803541367800_ljae344-B52","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/ced.14611","article-title":"Prevention of conjunctivitis in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single-centre experience","volume":"46","author":"Simonetti","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2024111803541367800_ljae344-B53","doi-asserted-by":"crossref","first-page":"e612-14","DOI":"10.1111\/jdv.17210","article-title":"Dupilumab and conjunctivitis: a case series of twenty patients","volume":"35","author":"Calabrese","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024111803541367800_ljae344-B54","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1080\/09546634.2022.2049588","article-title":"Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease","volume":"33","author":"Ferrucci","year":"2022","journal-title":"J\u00a0Dermatolog Treat"},{"key":"2024111803541367800_ljae344-B55","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","article-title":"Ocular surface diseases induced by dupilumab in severe atopic dermatitis","volume":"8","author":"Maudinet","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"2024111803541367800_ljae344-B56","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjd.20706","article-title":"New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab","volume":"186","author":"Bortoluzzi","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024111803541367800_ljae344-B57","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1007\/s12325-023-02573-3","article-title":"Analyses of dupilumab-related ocular adverse drug reactions using the WHO\u2019s VigiBase","volume":"40","author":"Hirai","year":"2023","journal-title":"Adv Ther"},{"key":"2024111803541367800_ljae344-B58","author":"National Institute for Health and Care Excellence"},{"key":"2024111803541367800_ljae344-B59","author":"National Institute for Health and Care Excellence"},{"key":"2024111803541367800_ljae344-B60","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jtos.2019.10.010","article-title":"Validation of a clinical assessment tool for cicatrising conjunctivitis","volume":"18","author":"Ong","year":"2020","journal-title":"Ocul Surf"},{"key":"2024111803541367800_ljae344-B61","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ajo.2009.09.013","article-title":"A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sj\u00f6gren\u2019s Syndrome International Registry","volume":"149","author":"Whitcher","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"2024111803541367800_ljae344-B62","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","article-title":"Grading of corneal and conjunctival staining in the context of other dry eye tests","volume":"22","author":"Bron","year":"2003","journal-title":"Cornea"},{"key":"2024111803541367800_ljae344-B63","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1167\/iovs.10-6997g","article-title":"The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction","volume":"52","author":"Geerling","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2024111803541367800_ljae344-B64","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1136\/bjophthalmol-2011-300771","article-title":"Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents","volume":"96","author":"Hamada","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"2024111803541367800_ljae344-B65","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40257-020-00577-1","article-title":"Conjunctivitis in dupilumab clinical trials for adolescents with atopic dermatitis or asthma","volume":"22","author":"Bansal","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2024111803541367800_ljae344-B66","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/ICO.0000000000002461","article-title":"Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up","volume":"40","author":"Bohner","year":"2021","journal-title":"Cornea"},{"key":"2024111803541367800_ljae344-B67","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/ICO.0000000000002866","article-title":"Prevalence and characteristics of dupilumab-induced ocular surface disease in adults with atopic dermatitis","volume":"41","author":"Felfeli","year":"2022","journal-title":"Cornea"},{"key":"2024111803541367800_ljae344-B68","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2340\/00015555-3121","article-title":"Eye complications during dupilumab treatment for severe atopic dermatitis","volume":"99","author":"Ivert","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"2024111803541367800_ljae344-B69","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/1203475420929920","article-title":"Incidence of conjunctivitis and other ocular surface disorders in patients with long-term dupilumab use","volume":"24","author":"Jo","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"2024111803541367800_ljae344-B70","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/09546634.2019.1711010","article-title":"Punctal stenosis associated with dupilumab therapy for atopic dermatitis","volume":"32","author":"Lee","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2024111803541367800_ljae344-B71","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/ICO.0000000000002262","article-title":"Dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"39","author":"Liberman","year":"2020","journal-title":"Cornea"},{"key":"2024111803541367800_ljae344-B72","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/DER.0000000000000461","article-title":"Blepharoconjunctivitis secondary to dupilumab successfully treated with itraconazole","volume":"30","author":"McCarthy","year":"2019","journal-title":"Dermatitis"},{"key":"2024111803541367800_ljae344-B73","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/bjophthalmol-2019-315010","article-title":"Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment","volume":"104","author":"Nahum","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"2024111803541367800_ljae344-B74","doi-asserted-by":"crossref","first-page":"100550","DOI":"10.1016\/j.ajoc.2019.100550","article-title":"Dupilumab-associated blepharoconjunctivitis","volume":"16","author":"Paulose","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2024111803541367800_ljae344-B75","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/ICO.0000000000002854","article-title":"Corneal perforation in patients under treatment with dupilumab for atopic dermatitis","volume":"41","author":"Phylactou","year":"2022","journal-title":"Cornea"},{"key":"2024111803541367800_ljae344-B76","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1038\/s41433-020-01379-9","article-title":"Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae","volume":"35","author":"Popiela","year":"2021","journal-title":"Eye (Lond"},{"key":"2024111803541367800_ljae344-B77","doi-asserted-by":"crossref","first-page":"e249019","DOI":"10.1136\/bcr-2022-249019","article-title":"Dupilumab-induced ocular surface disease: a primer","volume":"15","author":"Reji","year":"2022","journal-title":"BMJ Case Rep"},{"key":"2024111803541367800_ljae344-B78","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2147\/OPTH.S336978","article-title":"Clinical characteristics and treatment for dupilumab-related ocular complications in atopic dermatitis patients","volume":"16","author":"Tauqeer","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"2024111803541367800_ljae344-B79","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2024111803541367800_ljae344-B80","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01676830.2018.1553190","article-title":"Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis","volume":"38","author":"Yamane","year":"2019","journal-title":"Orbit"},{"key":"2024111803541367800_ljae344-B81","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jdcr.2018.10.016","article-title":"Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): a novel case report","volume":"5","author":"Zirwas","year":"2019","journal-title":"JAAD Case Rep"},{"key":"2024111803541367800_ljae344-B82","doi-asserted-by":"crossref","first-page":"e15059","DOI":"10.1111\/dth.15059","article-title":"Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single-center experience","volume":"34","author":"Napolitano","year":"2021","journal-title":"Dermatol Ther"},{"key":"2024111803541367800_ljae344-B83","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaip.2019.10.015","article-title":"Dupilumab-induced bilateral cicatricial ectropion in real life","volume":"8","author":"Nettis","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024111803541367800_ljae344-B84","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.alit.2018.12.012","article-title":"Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis","volume":"68","author":"Fukuda","year":"2019","journal-title":"Allergol Int"},{"key":"2024111803541367800_ljae344-B85","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/09273948.2018.1533567","article-title":"Dupilumab-induced follicular conjunctivitis","volume":"27","author":"Shen","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"2024111803541367800_ljae344-B86","doi-asserted-by":"crossref","first-page":"100848","DOI":"10.1016\/j.ajoc.2020.100848","article-title":"Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis","volume":"19","author":"Li","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2024111803541367800_ljae344-B87","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1684\/ejd.2021.4180","article-title":"Canalicular stenosis associated with dupilumab treatment for atopic dermatitis","volume":"31","author":"Loret","year":"2021","journal-title":"Eur J Dermatol"},{"key":"2024111803541367800_ljae344-B88","doi-asserted-by":"crossref","first-page":"101528","DOI":"10.1016\/j.ajoc.2022.101528","article-title":"Dupilumab-associated cicatrizing ocular disease","volume":"26","author":"Reddy","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2024111803541367800_ljae344-B89","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/bjd.20485","article-title":"British\u00a0Association of Dermatologists guidelines for the management of people with rosacea 2021","volume":"185","author":"Hampton","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024111803541367800_ljae344-B90","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ijwd.2019.10.001","article-title":"Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD)","volume":"5","author":"Raffi","year":"2019","journal-title":"Int J Womens Dermatol"},{"key":"2024111803541367800_ljae344-B91","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1111\/all.15439","article-title":"Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis","volume":"77","author":"Spekhorst","year":"2022","journal-title":"Allergy"},{"key":"2024111803541367800_ljae344-B92","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/bjd\/ljad011","article-title":"Successful dose reduction of dupilumab in atopic dermatitis","volume":"188","author":"Ardern-Jones","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024111803541367800_ljae344-B93","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/bjd\/ljad159","article-title":"Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry","volume":"189","author":"Spekhorst","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024111803541367800_ljae344-B94","doi-asserted-by":"crossref","first-page":"e15933","DOI":"10.1111\/dth.15933","article-title":"Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: a retrospective analysis","volume":"35","author":"Patruno","year":"2022","journal-title":"Dermatol Ther"},{"key":"2024111803541367800_ljae344-B95","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/eye.2017.208","article-title":"The Royal College of Ophthalmologists guidelines on serum eye drops for the treatment of severe ocular surface disease: executive summary","volume":"32","author":"Rauz","year":"2018","journal-title":"Eye (Lond)"},{"key":"2024111803541367800_ljae344-B96","author":"NHS England"},{"key":"2024111803541367800_ljae344-B97","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jaad.2022.04.009","article-title":"Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)","volume":"87","author":"Shi","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2024111803541367800_ljae344-B98","doi-asserted-by":"crossref","first-page":"e12221","DOI":"10.1002\/clt2.12221","article-title":"High dupilumab levels in tear fluid of atopic dermatitis patients with moderate-to-severe ocular surface disease","volume":"13","author":"Achten","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"2024111803541367800_ljae344-B99","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjd.20810","article-title":"Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials","volume":"186","author":"Wollenberg","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024111803541367800_ljae344-B100","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"key":"2024111803541367800_ljae344-B101","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1475-1313.2001.00575.x","article-title":"Grading scales for contact lens complications","volume":"18","author":"Efron","year":"1998","journal-title":"Ophthalmic Physiol Opt"},{"key":"2024111803541367800_ljae344-B102","volume-title":"Contact Lens Practice","author":"Efron","year":"2010","edition":"2nd edn"},{"key":"2024111803541367800_ljae344-B103","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjd.18179","article-title":"Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data","volume":"182","author":"de Wijs","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024111803541367800_ljae344-B104","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/ijd.14573","article-title":"Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients\u2019 records","volume":"59","author":"Wang","year":"2020","journal-title":"Int J Dermatol"},{"key":"2024111803541367800_ljae344-B105","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/ajd.13924","article-title":"Dupilumab-associated ocular surface disease: an interdisciplinary decision framework for prescribers in the Australian setting","volume":"63","author":"Foley","year":"2022","journal-title":"Australas J Dermatol"},{"key":"2024111803541367800_ljae344-B106","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ajoc.2017.06.017","article-title":"Cicatricial ectropion in a patient treated with dupilumab","volume":"7","author":"Barnes","year":"2017","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2024111803541367800_ljae344-B107","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jamadermatol.2018.3427","article-title":"Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management","volume":"154","author":"Levine","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2024111803541367800_ljae344-B108","first-page":"275","article-title":"Dupilumab induced limbal stem cell deficiency","volume":"14","author":"Mehta","year":"2021","journal-title":"Int Med Case Rep J"},{"key":"2024111803541367800_ljae344-B109","first-page":"303","article-title":"Dupilumab-associated blepharoconjunctivitis with giant papillae","volume":"13","author":"Vingopoulos","year":"2020","journal-title":"Int Med Case Rep J"},{"key":"2024111803541367800_ljae344-B110","volume-title":"Contact Lens Complications","author":"Efron","year":"2004","edition":"2nd edn"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae344\/59782985\/ljae344.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/6\/865\/60676357\/ljae344.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/6\/865\/60676357\/ljae344.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T22:55:29Z","timestamp":1731884129000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/191\/6\/865\/7749949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":110,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,9,5]]},"published-print":{"date-parts":[[2024,11,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae344","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,9,5]]}}}